疫苗接种前和接种时口服铁补充剂对缺铁肯尼亚女性免疫反应的影响 (DIVA_II)
Iron deficiency (ID) anemia (IDA) is a global public health problem, with the highest prevalence in Africa. Vaccines often underperform in low- and middle-income countries (LMIC), and undernutrition, including ID, likely plays a role. Recent studies have shown the importance of iron status in vaccine response. Intravenous iron given at time of vaccination improved response to yellow fever and COVID-19 vaccines in IDA Kenyan women. Whether oral iron treatment would have a similar beneficial effect on vaccine response is uncertain. Also, timing of oral iron treatment needs further investigation.
The co-primary objectives of this study are to assess 1) whether IDA in Kenyan women impairs vaccine response, and whether oral iron treatment improves their response; 2) the timing of oral iron treatment to improve vaccine response (prior to vaccination vs at time of vaccination).
We will conduct a double-blind randomized controlled trial in southern Kenya to assess the effects of iron supplementation on response to three single-shot vaccines: Johnson & Johnson COVID- 19 (JJ COVID-19), the quadrivalent meningococcal vaccine (MenACWY) and the typhoid Vi polysaccharide vaccine (Typhim Vi). Women with IDA will be recruited and randomly assigned to three study groups: group 1 (pre- treatment) will receive 100 mg oral iron as ferrous sulfate (FeSO4) daily on days 1-56; group 2 (simultaneous treatment) will receive matching placebo daily on days 1-28, and 100 mg oral iron as FeSO4 daily on days 29-56; and group 3 (control) will receive matching placebo daily on days 1-56. Women in all groups will receive the JJ COVID-19 vaccine, the MenACWY and the Typhim Vi vaccine on day 28. Cellular immune response and serology will be measured at 28 days after vaccination in all groups.
研究概览
地位
条件
研究类型
注册 (实际的)
阶段
- 不适用
联系人和位置
学习地点
-
-
Kenya
-
Nairobi、Kenya、肯尼亚、00200
- Jomo Kenyatta University Of Agriculture And Technology
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Willing and able to give informed consent for participation in the trial
- Female aged 18-49 years
- Moderate anemia (Hb <110 g/L, but not severely anemic with Hb <80 g/L)
- Iron deficient (ZnPP >40 mmol/mol haem)
- Anticipated residence in the study area for the study duration
Exclusion Criteria:
- Major chronic infecious disease (e.g., HIV infection);
- Major chronic non-infecious disease (e.g., Type 2 diabetes, cancer);
- Chronic medications;
- Use of iron-containing mineral and vitamin supplementation 2 weeks prior to study start;
- COVID-19 vaccine or confirmed COVID-19 infection within the past 2 years
- MenACWY vaccine in the past
- Typhim Vi vaccine in the past
- Pregnant (confirmed by rapid test during screening)
- Malaria (confirmed by rapid test) à study start will be postponed
学习计划
研究是如何设计的?
设计细节
- 主要用途:其他
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Pre-treatment group
Participants assigned to this group will receive 100 mg oral iron daily on study days 1-56. |
Iron supplements as 100 mg oral iron as FeSO4 given daily MenACWY vaccination given on day 28 to all participants Johnson & Johnson COVID- 19 (JJ COVID-19) vaccination given on day 28 to all participants Typhim Vi vaccination given on day 28 to all participants |
|
实验性的:Simultaneous treatment group
Participants assigned to this group will receive placebo daily on study days 1-28 and 100 mg oral iron daily on study days 29-56. |
Iron supplements as 100 mg oral iron as FeSO4 given daily MenACWY vaccination given on day 28 to all participants Johnson & Johnson COVID- 19 (JJ COVID-19) vaccination given on day 28 to all participants Typhim Vi vaccination given on day 28 to all participants matching placebo capsules given daily |
|
安慰剂比较:Control group
Participants assigned to this group will receive placebo daily on study days 1-56. |
Iron supplements as 100 mg oral iron as FeSO4 given daily MenACWY vaccination given on day 28 to all participants Johnson & Johnson COVID- 19 (JJ COVID-19) vaccination given on day 28 to all participants Typhim Vi vaccination given on day 28 to all participants matching placebo capsules given daily |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
JJ COVID-19 vaccine response
大体时间:Day 56
|
Anti-spike (S1) IgG and anti-receptor-binding domain (RBD) IgG against SARS-COV-2 |
Day 56
|
|
MenACWY vaccine response
大体时间:Day 56
|
Measurement of antibody response against serogroups A, C, W, and Y. |
Day 56
|
|
Typhoid vaccine response
大体时间:Day 56
|
Measurement of antibody response against Typhoid |
Day 56
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Hemoglobin
大体时间:Day 1
|
iron status |
Day 1
|
|
Hemoglobin
大体时间:Day 28
|
iron status |
Day 28
|
|
Hemoglobin
大体时间:Day 56
|
iron status |
Day 56
|
|
Serum ferritin
大体时间:Day 1
|
iron status |
Day 1
|
|
Serum ferritin
大体时间:Day 28
|
iron status |
Day 28
|
|
Serum ferritin
大体时间:Day 56
|
iron status |
Day 56
|
|
soluble transferrin receptor
大体时间:Day 1
|
iron status |
Day 1
|
|
soluble transferrin receptor
大体时间:Day 28
|
iron status |
Day 28
|
|
soluble transferrin receptor
大体时间:Day 56
|
iron status |
Day 56
|
|
Plasma iron
大体时间:Day 1
|
iron status |
Day 1
|
|
Plasma iron
大体时间:Day 28
|
iron status |
Day 28
|
|
Plasma iron
大体时间:Day 56
|
iron status |
Day 56
|
|
Total iron binding capacity
大体时间:Day 1
|
iron status |
Day 1
|
|
Total iron binding capacity
大体时间:Day 28
|
iron status |
Day 28
|
|
Total iron binding capacity
大体时间:Day 56
|
iron status |
Day 56
|
|
Transferrin saturation
大体时间:Day 1
|
iron status |
Day 1
|
|
Transferrin saturation
大体时间:Day 28
|
iron status |
Day 28
|
|
Transferrin saturation
大体时间:Day 56
|
iron status |
Day 56
|
|
C- reactive protein
大体时间:Day 1
|
inflammation status |
Day 1
|
|
C- reactive protein
大体时间:Day 28
|
inflammation status |
Day 28
|
|
C- reactive protein
大体时间:Day 56
|
inflammation status |
Day 56
|
|
alpha- 1- glycoprotein
大体时间:Day 1
|
inflammation status |
Day 1
|
|
alpha- 1- glycoprotein
大体时间:Day 28
|
inflammation status |
Day 28
|
|
alpha- 1- glycoprotein
大体时间:Day 56
|
inflammation status |
Day 56
|
|
Retinol binding protein
大体时间:Day 1
|
Vitamin A status |
Day 1
|
|
Retinol binding protein
大体时间:Day 28
|
Vitamin A status |
Day 28
|
|
Retinol binding protein
大体时间:Day 56
|
Vitamin A status |
Day 56
|
|
Plasma zinc
大体时间:Day 1
|
Zinc status |
Day 1
|
|
COVID-19 specific T cell response
大体时间:Day 28
|
QuantiFERON SARS-CoV-2 whole blood assay - detection of IFN-gamma |
Day 28
|
|
COVID-19 specific T cell response
大体时间:Day 56
|
QuantiFERON SARS-CoV-2 whole blood assay - detection of IFN-gamma |
Day 56
|
|
COVID-19 specific T cell response
大体时间:Day 28
|
ELISpot assay on isolated peripheral blood mononuclear cells |
Day 28
|
|
COVID-19 specific T cell response
大体时间:Day 56
|
ELISpot assay on isolated peripheral blood mononuclear cells |
Day 56
|
|
Typhim Vi specific B-cell response
大体时间:Day 28
|
ELISpot assay on isolated peripheral blood mononuclear cells |
Day 28
|
|
Typhim Vi specific B-cell response
大体时间:Day 56
|
ELISpot assay on isolated peripheral blood mononuclear cells |
Day 56
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.